backThe TPP is an agreement among 12 Pacific Rim countries – Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam – that would create, upon implementation, an integrated regional economy accounting for 40 percent of global GDP. The agreement also is important, because it sets a textual baseline for on-going discussions concerning other multilateral trade negotiations, like the Transatlantic Trade and Investment Partnership (T-TIP) between the United States and the EU.
On November 5, 2015, the Obama Administration released the working text of the TPP and notified Congress of the President’s intent to sign the agreement. Implementation of TPP, however, depends on Congressional approval and is by no means a sure thing. Now that the dust has settled (and now that interested parties have had an opportunity to review the previously-confidential text of the TPP agreement), this presentation will discuss the political landscape affecting TPP (and likely timing of any vote by the U.S. Congress). The presentation also will review aspects of TPP that are likely to impact Life Sciences companies, including country-of-origin rules, intellectual property rights, data transfers, and technical regulations and standards.
Program Speakers
- J. Michael Taylor
- Jeffrey M. Telep
- Bonnie B. Byers
- Joseph Laroski
For more information, contact:
Glenda R. Smith
Senior Paralegal
King & Spalding LLP
1180 Peachtree Street NE
Atlanta, GA 30309
+1 404 572 3017 Direct
glendasmith@kslaw.com
The King & Spalding University e-Learn Series offers monthly one-hour interactive panel presentations. There is no expense to participants.